Every 8-K that INHIBITOR THERAPTICS INC (INTI) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow INTI and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full INTI filings page.
Inhibitor Therapeutics, Inc. (INTI) reported the results of its 2026 Annual Meeting of Stockholders held on September 15, 2026. Stockholders elected six directors — Francis E. O’Donnell, Samuel J. Sears, Niraj Vasisht, Michelle Yanez, Michael Jerman and Ronald E. Osman — each to serve a one-year term expiring at the 2027 annual meeting.
Stockholders ratified the appointment of Cherry Bekaert LLP as independent registered public accounting firm for the year ending December 31, 2026. They also approved the 2025 Share Incentive Plan, and, in a non-binding advisory vote, approved the Company’s executive compensation. In addition, stockholders indicated a preferred frequency of future say-on-pay votes of both one year and three years, with the largest support for a three-year frequency.
Inhibitor Therapeutics, Inc. furnished an update on its itraconazole program for Gorlin Syndrome, covering clinical progress, formulation strategy and intellectual property plans. The company is running a three-way crossover pharmacokinetic study in healthy adults in Malaysia under fasting conditions, in collaboration with Avior Bio.
Period 2 dosing is scheduled for April 10, 2026 and Period 3 for April 24, 2026, with plasma samples expected to be shipped for bioanalysis on or about May 1, 2026. Inhibitor believes this PK study is expected to be the final clinical study before a planned New Drug Application for surgically eligible basal cell carcinomas in BCCNS.
The program uses a proprietary amorphous itraconazole formulation intended to improve solubility and absorption versus conventional crystalline drug. Inhibitor is also preparing a new global patent application on this formulation, which it expects would be owned by the company without ongoing royalty obligations and would complement its existing oncology-focused IP portfolio.
Inhibitor Therapeutics, Inc. entered into a Securities Purchase Agreement with an institutional investor to raise $3,000,000. The company agreed to sell 12,000,000 shares of common stock and issue a warrant to purchase up to 7,000,000 additional shares at $0.25 per share and accompanying warrant.
The warrant will be exercisable for three years at an exercise price of $0.35 per share, which could provide up to an additional $2,450,000 in gross proceeds if fully exercised. As of the filing date, the financing had not yet closed, and the investor agreed under a lock-up to refrain from selling the financing and warrant shares for nine months after the SPA date or until a change in control.
Inhibitor Therapeutics (INTI) reported two corporate actions. The company entered a performance-based master services agreement with Frameshift Management, Inc. to provide biostatistics, regulatory, business development and strategic consulting supporting its basal cell carcinoma programs in Gorlin’s syndrome. Services commenced on October 21, 2025, with compensation at a previously agreed rate and unvested equity compensation realized only after requirements described in the agreement.
The Board also approved the 2025 Equity Incentive Plan, reserving up to 20,000,000 shares of common stock for awards, including options, RSUs, and other stock- or cash-based awards. Shareholder approval is planned within 12 months of adoption; if not received in time, the plan and any awards made under it will terminate.